XOMA Royalty Corporation reported its first quarter 2025 financial results, showing a significant increase in total income and revenues, which rose to $15.9 million from $1.5 million in the same period of 2024. The increase was primarily attributed to income from the effective interest rate method related to VABYSMO®, a $4.0 million milestone associated with Day One and Ipsen's MAA filing with the EMA, a $4.0 million payment from a collaboration agreement with Takeda, and $1.5 million in estimated royalties related to OJEMDA™. Net income for the quarter ending March 31, 2025, was $2.4 million, contrasting with a net loss of $8.6 million in the first quarter of 2024. The company also highlighted $18.0 million in cash receipts during the quarter, including $13.4 million from royalty receipts. In terms of business development, XOMA acquired an economic interest in Castle Creek Biosciences' D-Fi (FCX-007) through a syndicated royalty financing transaction and successfully sold all unpartnered Kinnate assets. The company is focused on generating shareholder value through strategic cash deployment, expense control, and share repurchases.